Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4788 companies, A–Z).
Werewolf Therapeutics released early clinical data for its two INDUKINE candidates, WTX-124 and WTX-330, presented at the Society for Immunotherapy of Cancer's 2026 Annual Meeting. The company said it has aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for WTX-124 and that WTX-330 was well tolerated. The filing contains no financial results, and the data come from small early-stage trials, so shareholders will mainly weigh the programs' future development prospects.
WTX-124 recommended Phase 2 dose set at 18 mg IV Q2W, aligned with the FDA, for monotherapy and combination with pembrolizumab
WTX-124 monotherapy produced one durable confirmed complete response in a patient with ICI-resistant cutaneous squamous cell carcinoma, ongoing for approximately three years
WTX-330 data from 24 patients showed a confirmed partial response in a patient with gallbladder cancer, per the filing
Faeth Therapeutics filed a November 9, 2026 corporate presentation with topline results from its single-arm Phase 2 PIK-201 trial of PIKTOR plus paclitaxel in advanced endometrial cancer. The filing says the results are preliminary and that PIKTOR is investigational and not approved, so the data does not yet establish a commercial outlook for shareholders.
Confirmed objective response rate of 33% (12 of 36 efficacy-evaluable patients), with a 10.30.26 efficacy data cut
Preliminary median progression-free survival of 7.4 months (95% CI 5.3, not reached) across 42 treated patients
27 of 42 patients (64%) had a grade 3 or higher treatment-related adverse event, per the 10.23.26 safety data cut
Cabaletta Bio released new Phase 1/2 clinical data on its investigational cell therapy rese-cel, presented at the ACR Convergence 2026 meeting, covering dermatomyositis, lupus nephritis, and systemic sclerosis patients followed up to one year. The company reported that 100% (6/6) of dermatomyositis patients maintained immunomodulator-free responses through one year, and it reiterated plans for registrational topline results in the second half of 2027 and a planned BLA submission in the first quarter of 2028. The sample sizes are small, and the filing does not report any financial figures.
100% (6/6) of dermatomyositis patients maintained immunomodulator-free, moderate-to-major TIS responses through one year
71% (5/7) of systemic sclerosis patients achieved rCRISS-50 at one year; five patients with interstitial lung disease showed 9% mean FVC improvement
Grade 2 cytokine release syndrome was reported in 6% (4/71) of 71 patients; no IEC-HS was reported
Registrational topline results expected in 2H 2027; planned BLA submission in myositis in 1Q 2028
Perspective Therapeutics (CATX) filed an 8-K on November 6, 2026 with a press release and poster presenting updated interim results from its Phase 1/2a trial of [212Pb]lapemelanotide zapixetar (VMT01) in unresectable or metastatic melanoma, presented at the SITC 41st Annual Meeting in Phoenix. The filing reports antitumor activity at the 3.0 mCi dose and no dose-limiting toxicities across 20 patients, but the sample is small and the company says it is still evaluating dose optimization. The update is early-stage clinical data and contains no financial results or guidance.
Data cover 20 patients in three monotherapy cohorts as of the September 18, 2026 data cutoff; no dose-limiting toxicities were reported
At the 3.0 mCi dose, 2 of 8 patients had objective partial responses and the disease control rate was 75%
Grade 3 or higher treatment-emergent adverse events occurred in 5 of 20 patients (25%), none considered treatment-related
Sunshine Silver Mining & Refining announced it has completed its 50,000-meter infill drill program at the Sunshine Mine in Idaho and reported further drill results, including intercepts above 1,000 grams per tonne silver. The company says the results will feed an updated Mineral Resource Estimate expected in the first quarter of 2027, a feasibility study targeted for the second quarter of 2027, and a planned return to production in late 2028. The filing contains no revenue, earnings or guidance figures, and the timelines are company expectations.
Program comprised approximately 51,250 meters in 218 holes; the company reported 7,069 gpt silver over 1.00 meter in the NY Boy Vein as a highlighted result
Updated Mineral Resource Estimate expected in Q1 2027; Sunshine Mine Feasibility Study targeted for Q2 2027
Planned return to production in late 2028; three rigs continue underground drilling
Freeport-McMoRan's Board of Directors approved a $4.5 billion expansion and modernization program for its wholly owned Bagdad copper and molybdenum operation in northwest Arizona. The filing says the project would lift annual long-term copper output to over 400 million pounds, about 225 million pounds more, with initial production targeted for mid-2030. For shareholders, this is a large, multi-year capital commitment, with planned spending to be incorporated into the company's updated capital expenditure outlook and classified as discretionary.
Future incremental capital costs for a new concentrator, mining equipment and expanded infrastructure are expected to approximate $4.5 billion.
Annual long-term production would exceed 400 million pounds of copper (about 225 million pounds incremental) and over 20 million pounds of molybdenum (about 12 million pounds incremental).
Construction is expected to take about 3.5 years, with about 20% of project costs funded in 2027, 30-35% in 2028 and the balance in 2029-2030.
Project break-even economics are supported at a copper price of approximately $4.00 per pound, and the company expects a roughly 20% reduction in long-term unit net cash costs.
TOP Financial Group Limited issued a November 3, 2026 press release addressing unusual recent fluctuations in its stock price. The company said its operations are progressing normally and that it is not aware of any material, undisclosed corporate developments that would explain the volatility. The release also gave updates on plans for a U.S. expansion, including a planned artificial intelligence research and development center in Silicon Valley, California, which the filing describes as forward-looking and subject to risks.
Press release dated November 3, 2026 responds to recent unusual fluctuations in TOP's stock price
Company states it is not aware of any material, undisclosed developments that would account for the volatility
Global headquarters previously announced in Houston, Texas; a planned AI Research and Development Center in Silicon Valley, California is in progress
Co-Chief Executive Officer Jennifer Hoi Ling Tam said long-term value relies on strategic execution rather than short-term stock performance
Bitmine said its total crypto, cash and marketable securities and moonshot holdings reached $14.5 billion as of November 1, 2026, including 6,060,506 ETH. The update is a holdings and operations announcement, not an earnings report, and it contains no revenue, profit or guidance figures.
ETH holdings of 6,060,506 tokens, or 4.9% of the 122.2 million ETH supply, as of November 1, 2026
Total cash and marketable securities of $498 million, plus $180 million in Beast Industries and $82 million in Eightco Holdings
5,227,037 ETH staked, valued at $11.8 billion at $2,261 per ETH; projected annualized staking reward of $415 million at full staking
Strategy Inc reported its weekly update for October 26 to November 1, 2026, in which it bought 811 bitcoin for $65.5 million using net proceeds from MSTR Stock sales. It also repurchased about 2.09 million STRC preferred shares for $208.2 million, funded from USD Cash. The filing shows bitcoin holdings of 849,327 BTC and a USD Reserve balance of $4.79 billion as of November 1, 2026.
Bought 811 bitcoin for $65.5 million at an average price of $80,846; aggregate holdings reached 849,327 BTC
Sold 1,178,552 MSTR Stock shares for $164.0 million in net proceeds; $98.5 million allocated to USD Cash
Repurchased 2,092,035 STRC preferred shares for $208.2 million; $748.6 million remains under the preferred repurchase program
USD Reserve stood at $4.79 billion and USD Cash at $132.7 million as of November 1, 2026
U.S. GoldMining provided an update on the State of Alaska-led West Susitna Access Project (WSAP), a 78.5-mile road that would connect its Whistler project to regional infrastructure. The U.S. Army Corps of Engineers has issued a public notice on the road's Section 404 permit application, closed the comment period, and is evaluating the application under emergency procedures. The filing is a development update with no change to financial results, and the road's completion and permit issuance remain uncertain.
On September 25, 2026, the USACE issued a Public Notice on AIDEA's Section 404 permit application for the WSAP; the comment period is now closed.
USACE determined the permit request qualifies for special emergency permitting procedures, which the filing says is expected to significantly reduce normal processing time.
AIDEA recently authorized up to $25 million for geotechnical drilling and permitting, hydrologic and engineering work for the WSAP.
Cullen/Frost Bankers said it will voluntarily move the listings of its common stock and Series B preferred depositary shares from the New York Stock Exchange to the Texas Stock Exchange. Trading on the TXSE is expected to begin November 12, 2026, and the tickers CFR and CFR.PrB will stay the same, with the company stating no shareholder action is required.
NYSE trading in common stock (CFR) and depositary shares (CFR.PrB) is expected to end at market close on November 11, 2026.
TXSE trading is expected to begin at market open on November 12, 2026, under the existing symbols.
The filing states no action is required from Cullen/Frost shareholders for the transfer.
The company reported $54.5 billion in assets at September 30, 2026.
Azitra amended the Phase 1/2 trial of its ATR-04 candidate to include patients with rash caused by KRAS and MEK inhibitors and neurofibromatosis type 1 patients with MEK inhibitor-associated rash, and shortened washout periods for antibiotics and steroids. The filing says the changes broaden the potential treatment opportunities for ATR-04 and are intended to speed patient recruitment, but it gives no financial figures and no timeline for results.
Eligibility now includes patients with rash associated with KRAS and MEK inhibitors, plus NF1 patients with MEK inhibitor-associated rash.
Washout periods for antibiotics and steroids are shortened under the amendments.
Cohort 2 is expected to enroll approximately 24 patients receiving once-daily treatment for 28 days, following the safety review committee's recommendation to proceed.
Azitra cites about 85,000 U.S. patients a year on KRAS or MEK inhibitors, compared with about 220,000 on EGFR inhibitors.
Centrus Energy said its Oak Ridge, Tennessee plant has completed and shipped the first new centrifuge for its multibillion-dollar uranium enrichment expansion, with components to be assembled in Ohio. The company said this and a complete domestic supply chain were achieved ahead of its previously announced year-end target, but the filing contains no financial results or updated guidance.
First new centrifuge completed and shipped from Oak Ridge on October 29, 2026, ahead of the previously announced year-end target.
Centrus said it completed its acquisition of Westerman Holdings, a supplier of centrifuge casings, earlier in October 2026.
The company announced a $560 million investment in January 2026 to expand its Oak Ridge plant, and first new capacity in Ohio is expected to come online in 2029.
Oncolytics Biotech reported updated Cohort 4 data from its Phase 1/2 GOBLET study of pelareorep with atezolizumab in second-line and later squamous cell anal cancer. The company says the median duration of response is about 15 months, compared with 9.5 months for an FDA-approved retifanlimab monotherapy in a similar population, but the filing offers no revenue, earnings, or financing figures and the results remain early clinical data.
Median duration of response is approximately 15 months; median overall survival has not yet been reached
All patients who responded to treatment survived beyond 12 months, according to the company
The filing says the 15-month estimate comes from the company's internal calculations for this draft
Company cites FDA Fast Track Designation and recent FDA interactions as support for registrational development
Bitmine Immersion Technologies said in a press release furnished under Item 7.01 that its crypto, cash and marketable securities, and moonshot holdings totaled $15 billion as of October 25, 2026. The company also reported buying back 2.04 million shares in the past week and 22.9 million shares so far in 2026 for $399.6 million. The filing notes that these values depend on volatile digital asset prices and that repurchases are subject to market conditions and may be suspended at any time.
Total holdings of $15 billion as of October 25, 2026, including 6,051,933 ETH valued at $2,356 per ETH, 215 Bitcoin, and $514 million in total cash and marketable securities
Moonshot stakes include $180 million in Beast Industries and $76 million in Eightco Holdings (NASDAQ: ORBS)
Repurchased 2.04 million shares in the past week at an average price of $22.48; 22.9 million shares repurchased in 2026 for $399.6 million at an average of $17.48
5,227,037 ETH staked, representing $12.3 billion; projected annualized staking reward of $368 million if all ETH is staked
Aptevo reported that ten patients with newly diagnosed acute myeloid leukemia treated with mipletamig plus venetoclax and azacitidine have advanced to allogeneic stem cell transplant. The company said the data is a clinical update from its Phase 1b RAINIER trial and one earlier dose expansion trial, and it does not include any financial results or guidance.
Ten of 47 (21%) evaluable frontline patients treated with mipletamig plus venetoclax and azacitidine proceeded to transplant, including nine from RAINIER and one from the prior dose expansion trial.
The company cited the Phase 3 VIALE-A trial, in which three of 286 patients (0.7%) receiving venetoclax and azacitidine alone later underwent transplant, and noted that cross-trial comparisons have limits.
Aptevo expects to complete RAINIER dose optimization by year-end 2026 and discuss next steps with regulators in the first half of 2027.
Strive said it bought 6,182 bitcoin between October 17 and October 23, 2026, at an average price of about $82,732 per bitcoin, including fees and expenses. Its bitcoin holdings rose from 36,818 to 43,000 and its cash and cash equivalents rose from $317.5 million to $504.4 million over the same period, as of October 16 and October 23. Shareholders are affected by the larger treasury and the increase in Class A common shares outstanding to 118,113,644.
Bought 6,182 bitcoin from October 17 to October 23, 2026, at an average of about $82,732 per bitcoin
Bitcoin held rose from 36,818 to 43,000 as of October 23, 2026
Cash and cash equivalents rose $186.9 million to $504.4 million as of October 23, 2026
Class A common stock outstanding rose by 3,266,034 shares to 118,113,644; 7,000,000 SATS Stock shares were added
Eikon Therapeutics presented updated data from its Phase 2 TeLuRide-005 trial of EIK1001 with pembrolizumab and chemotherapy at the 2026 ESMO Congress, in 72 patients with previously untreated stage 4 non-small cell lung cancer. The filing reports a 63.1% pooled objective response rate and 48.6% rate of Grade 3 or higher treatment-related adverse events, with no new financial results. The data are a clinical update that does not change the company's reported financials, but they set the outlook for its Phase 2/3 TeLuRide-008 trial, with a dose-selection interim analysis expected in the second half of 2027.
Pooled objective response rate of 63.1% and disease control rate of 89.2% in 65 efficacy-evaluable participants, at an October 1, 2026 data cutoff
Squamous cohort objective response rate of 72.4% and median duration of response of 12.9 months; non-squamous cohort objective response rate of 55.6%
Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, and 6.9% discontinued treatment due to them
Interim analysis to select the single EIK1001 dose for TeLuRide-008 is expected in the second half of 2027
Black Hills Corp. announced the planned name and ticker for the combined company if its merger with NorthWestern Energy receives final Montana regulatory approval and closes. Shareholders need take no action, and BKH shares continue trading under their current symbol while the merger is pending.
Black Hills would be renamed Bright Horizon Energy Corporation and trade on the NYSE as HZN after the merger completes.
NorthWestern Energy would become a wholly owned subsidiary of Bright Horizon Energy.
The Montana Public Service Commission is expected to consider the merger before November 12, 2026.
Shareholders of both companies, the Nebraska and South Dakota commissions, FERC and Hart-Scott-Rodino clearance have already approved or cleared the merger.
Cycurion filed three press releases furnished as exhibits: a shareholder letter from CEO L. Kevin Kelly on its predictive intelligence strategy, a report of about $383,000 in new and expanded Digital Ally law enforcement contracts, and notice of a third-quarter earnings call on November 16, 2026. The filing reports no third-quarter financial results, so shareholders still lack the company's latest revenue or profit figures.
Digital Ally secured about $383,000 in new and expanded contracts over the past 30 days, per the October 21, 2026 release.
Third-quarter 2026 earnings call set for Monday, November 16, 2026 at 9:30 AM ET; written questions due by November 13, 2026.
The CEO letter says Nasdaq bid-price compliance was regained, with a Discretionary Panel Monitor running through October 1, 2027.
The letter states future financings may be dilutive and that about 80% of the business is currently services.
Korro Bio announced preclinical results for KRRO-111, its development candidate for alpha-1 antitrypsin deficiency (AATD), in an October 22, 2026 press release filed as Exhibit 99.1. The company says the studies, which were conducted in mice and human liver cells, show RNA editing and reduced toxic Z-AAT protein, and it expects a regulatory submission in the first half of 2027. The filing reports no financial results, and the data are preclinical, so they do not show how the drug will perform in people.
In repeat-dose mouse studies, SERPINA1 mRNA editing reached 96% and total AAT concentrations were about 6-fold versus vehicle at Day 57.
Whole liver Z-AAT levels fell 95% relative to vehicle control in immunocompetent C57BL/6-PiZ mice at Day 57.
Korro expects to submit a regulatory filing for KRRO-111 in the first half of 2027.
Mannatech's audit committee dismissed BDO USA as its independent auditor effective October 15, 2026, and engaged CBIZ CPAs for fiscal 2026. BDO's report on the 2025 financial statements included an explanatory paragraph on substantial doubt about the company's ability to continue as a going concern, and the filing states there were no disagreements or reportable events with BDO.
Audit committee approved BDO's dismissal and CBIZ's engagement on October 15, 2026.
BDO's 2025 audit report contained a going-concern explanatory paragraph; its 2024 report did not.
The filing reports no disagreements or reportable events with BDO in 2024, 2025 or the interim period through October 15, 2026.
BDO's letter on the change will be filed by amendment to this Form 8-K.
Arcus Biosciences presented new data from its ARC-20 platform study of casdatifan, alone or in combination, for clear cell renal cell carcinoma, using a data cutoff of September 4, 2026. The filing reports response, progression and survival figures across first-line, second-line and late-line cohorts, with no unexpected safety signals cited for each regimen.
Second-line casdatifan plus cabozantinib (n=43): median PFS 14.5 months, 18-month landmark overall survival 77%, cORR 44%
First-line casdatifan plus zimberelimab (n=30): cORR 50%, landmark PFS 69% at 12 months, primary progression 6.7%
Late-line casdatifan monotherapy (n=121): median overall survival 35 months, median PFS 13 months, cORR 36%
Hilton notified the New York Stock Exchange that it will voluntarily transfer the listing of its common stock to the Nasdaq Global Select Market. The stock will keep the ticker HLT, and no action is required from shareholders. The filing reports no change to financial results or business strategy, so the move mainly affects where shares are listed and traded.
NYSE trading in Hilton common stock is expected to end at market close on November 4, 2026.
Trading on Nasdaq is expected to begin at market open on November 5, 2026, under the existing ticker HLT.
The press release says the transfer does not alter Hilton's business strategy or capital allocation priorities.
Hilton's CEO Chris Nassetta said the company is grateful to the NYSE for its longstanding partnership.
Effective October 19, 2026, the fund may invest up to 10% of Managed Assets in non-U.S. dollar securities and up to 20% in contingent convertible securities, and may gain exposure to Regulation S and TEFRA bonds through wholly owned Cayman Islands subsidiaries. The filing also adds related risk factors, including foreign currency, liquidity, subsidiary and tax risks, which may affect shareholder returns.
New policy allows up to 10% of Managed Assets in non-U.S. dollar denominated securities; prior policy allowed only U.S. dollar securities.
New policy allows up to 20% of Managed Assets in contingent capital (CoCo) securities; prior policy had none.
TEFRA Bond Subsidiary may hold up to 25% of total assets, and the Regulation S Subsidiary may invest without limitation in Regulation S securities.
Supplemental risk factors are effective August 31, 2026, and cover foreign currency, Regulation S liquidity, TEFRA bond and subsidiary tax risks.
Jaguar Uranium Corp. announced an independent mineral resource estimate for its 100%-owned Laguna Salada uranium-vanadium deposit in Argentina, with an effective date of October 5, 2026. The supporting technical report summary is dated October 16, 2026, and the company states it has not declared any mineral reserves and the report contains no economic analysis, so the estimate does not by itself establish economic viability.
Press release announcing the estimate issued October 13, 2026; estimate effective October 5, 2026
Technical report summary dated October 16, 2026, prepared by Caracle Creek Chile SpA and Atticus Geoscience Consulting Ltd.
Report uses a US$12.08/t NSR cut-off value; the company has declared no mineral reserves and the report includes no economic analysis
Filing warns inferred resources carry high geological uncertainty and may not convert to reserves
Tron Inc. said it was elected as one of the 27 Super Representative nodes on the TRON blockchain, ranking #27 as of October 18, 2026, with 0.76 billion delegated TRX tokens. The company says it will move from TRX treasury holdings into active network roles, including block production, transaction validation, network security and on-chain governance, through a wholly owned subsidiary. The filing includes no revenue, cost or profit figures, so its effect on shareholder value is not quantified.
Elected as one of 27 Super Representative nodes on the TRON network; ranked #27 as of October 18, 2026
Holds 0.76 billion delegated TRX tokens, per the press release
Operations will run through a wholly owned subsidiary: block production, transaction validation, network security and governance
Company says the role aims to generate recurring on-chain revenue, but the filing gives no revenue figures
Ainos's board approved Second Amended and Restated Bylaws on October 14, 2026, effective immediately, dividing directors into three classes with staggered three-year terms. The board also amended its Corporate Governance Policies to reflect the new structure, so shareholders will elect only one class of directors at each annual meeting.
Board unanimously approved the restated bylaws on October 14, 2026, effective immediately
Class I (term expires at 2026 annual meeting): Ting-Chuan Lee, Chun-Jung Tsai, Chung-Yi Tsai
Class II (term expires at 2027 annual meeting): Yao-Chung Chiang, Pao-Sheng Wei; Class III (term expires at 2028 annual meeting): Chun-Hsien Tsai, Wen-Han Chang
Amended Corporate Governance Policies filed as Exhibit 99.1; restated bylaws filed as Exhibit 3.1
Lion Copper Corp. said it received approval from Nasdaq to list its common shares on the Nasdaq Capital Market under the symbol LCU, with trading expected to begin October 19, 2026, subject to customary listing conditions. The shares will keep trading on the Canadian Securities Exchange, and OTCQB quotation is expected to end once Nasdaq trading starts. The filing does not include financial results or a financing.
Nasdaq trading under LCU expected to start at market open on Monday, October 19, 2026
Shares will continue to trade on the Canadian Securities Exchange under LCU
OTCQB quotation under LCGMF expected to cease when Nasdaq trading begins
Company says no action is required from shareholders
Etoiles Capital Group Co., Ltd. announced on October 16, 2026 that it has completed its change of jurisdiction from the Cayman Islands to Nevada, approved by shareholders at the October 15, 2026 annual general meeting. Each Class A ordinary share will convert into one share of common stock effective October 19, 2026, and no action is required from shareholders. Trading in the shares has been suspended since October 6, 2025 and remains suspended, with no resumption date given, so shareholders cannot trade until it resumes.
Shareholders approved the domestication at the annual general meeting held October 15, 2026.
Effective October 19, 2026, each Class A ordinary share converts into one share of common stock of the Nevada company.
Trading has been suspended since October 6, 2025 and remains suspended; the CUSIP changes to 29771T102.
Rezolute said the open-label Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism is fully enrolled, with 16 participants, and topline data are expected in mid-December 2026. The filing contains no new efficacy data, and the company said it will continue its expanded access program.
Study is fully enrolled with approximately 16 participants; topline data expected mid-December 2026
Earlier in 2026, 7 of the first 8 participants met the primary endpoint responder criterion
The eighth participant died one week after enrollment from cancer progression and is counted as a non-responder
Statistical significance requires a response rate of at least 56% (95% CI of 30-80%) for 16 participants
Arrive AI announced on October 12, 2026 the formation of Arrive AI Defense, a new division to bring its autonomous delivery infrastructure to defense, military, diplomatic and national security customers. Chief Strategy Officer Neerav Shah will lead the division, and the company says it may pursue non-dilutive government funding. The filing states no government funding awards or defense contracts have been announced, so the division has no disclosed financial impact yet.
Arrive AI Defense announced October 12, 2026; Neerav Shah, Chief Strategy Officer, will lead it
Planned applications include battlefield resupply, U.S. embassy Arrive Points and military medical logistics
Company intends to evaluate SBIR and STTR programs and other government funding, with no awards announced
Filing states there can be no assurance the company will qualify for or receive such funding
CervoMed reported initial 12-week biomarker data from its open-label Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia, presented October 12, 2026 at the ISFTD annual meeting. The average plasma neurofilament light chain level declined, but the trial has 25 participants and no placebo or control group during the open-label period, so the results are early. The filing contains no revenue or financial results, and the company expects 24-week biomarker data in November 2026 and topline clinical data in the first quarter of 2027.
Mean plasma NfL change was about -3.1 pg/mL over the first 12 weeks across 25 participants, with most of the decline between weeks six and 12.
In an exploratory subgroup with baseline NfL at or above the median (n=13), mean NfL change was about -5.7 pg/mL over 12 weeks; GFAP levels were stable.
One patient met protocol criteria for discontinuation due to elevated liver enzymes; the company reported no new safety signals.
24-week biomarker data will be presented at CTAD in November 2026; clinical data are expected in the first quarter of 2027.
Runway Growth Finance Corp. released a portfolio update for the quarter ended September 30, 2026, reporting $139.4 million in liquidity events and about $8.5 million in follow-on funding to existing portfolio companies. The update also covers the restructuring of Marley Spoon SE, where unfunded commitments were converted into a bridge loan, and management's stated plan to use share repurchases to address the gap between its share price and portfolio fundamentals. The release does not include revenue, earnings, or guidance figures.
Four liquidity events totaled $139.4 million, including a full $72.3 million repayment of the senior secured term loan to 3PL Central LLC (dba Extensiv).
Four follow-on investments totaled about $8.5 million, including about $5.6 million funded on a restructured Marley Spoon SE bridge loan of €8.1 million.
Marley Spoon announced a 21% workforce reduction and is advancing a revised operating plan; Runway continues to evaluate multiple paths to liquidity.
Co-CEO Michael Rovner said share repurchases are part of the plan to close the valuation gap, but the filing gives no repurchase amount or timing.
iBio presented preclinical data from an eight-week obese non-human primate study of IBIO-610, a potential first-in-class Activin E antibody, at the EASD Annual Meeting on October 1, 2026. The company reported that fat made up 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone, and it plans to begin first-in-human studies in the first half of 2027. The data are early animal results, and the filing notes they may not be replicated in humans.
Lean mass was 6% of weight lost with IBIO-610 plus semaglutide, versus 22% with semaglutide alone (eight-week study, n=6 per group)
At week 8, fat accounted for 93% of weight lost with IBIO-610 plus semaglutide, versus 77% with semaglutide alone
IBIO-610 reduced serum levels of active Activin E by 97% at week 8 after a single intravenous dose, and had a 33.2-day half-life in NHPs
First-in-human studies are planned to begin in the first half of 2027
Emerson Electric said it changed its method of accounting for pension and other postretirement benefit plans to mark-to-market, effective for fiscal 2026, and filed recast historical results. The change adds $8 million to pretax earnings for the nine months ended June 30, 2026, and the company expects a pretax mark-to-market gain of less than $5 million in the fourth quarter of fiscal 2026, which was not in its previous outlook. The change has no effect on cash flows, plan funding or benefits payable.
Nine-month pretax earnings rise $8 million; after-tax $6 million, or $0.01 per share
Fourth-quarter fiscal 2026 mark-to-market gain expected to be less than $5 million pretax
Adjusted earnings per share will exclude the annual mark-to-market adjustment
Change applied retrospectively; recast results are in Exhibit 99.1 and are not a restatement
MSG Rangers Corp., formerly MSGS Spinco, Inc., disclosed that its Form 10 registration statement became effective on October 9, 2026, and that Joseph M. Cohen was appointed to its board and to the Audit and Compensation Committees. The distribution of its shares to MSG Sports stockholders is expected to take effect at 11:59 p.m. New York City time on October 26, 2026, when the company will own the New York Rangers business and begin trading on the NYSE as MSGR.
Registration statement effective October 9, 2026 at 4:00 p.m. New York City time; distribution expected October 26, 2026 at 11:59 p.m.
Record date is October 20, 2026; holders receive one Spinco Class A share for every two MSG Sports Class A shares held
Joseph M. Cohen appointed director effective October 9, 2026, and named to the Audit and Compensation Committees
Dolan Family Group expected to hold about 63.4% of total voting power after the distribution
On October 5, 2026, the Audit Committee dismissed WithumSmith+Brown as Elauwit Connection's independent auditor, effective immediately, and engaged MPB Global LLP for the fiscal year ending December 31, 2026. The filing says WithumSmith+Brown issued no report after March 31, 2026 on the 2025 financial statements, and it cites material weaknesses in internal control over financial reporting disclosed in the company's 2025 Form 10-K. Shareholders may want to watch for the new auditor's work and any further disclosure about those weaknesses.
Audit Committee approved the dismissal of WithumSmith+Brown on October 5, 2026, effective immediately.
WithumSmith+Brown was engaged August 26, 2025, and did not issue a report after March 31, 2026 on the 2025 financial statements.
Its 2025 audit report had no adverse opinion or disclaimer and was not qualified or modified.
MPB Global LLP was engaged on October 5, 2026, as the new auditor for fiscal 2026; the filing cites material weaknesses in internal control from the 2025 Form 10-K.
Universal Safety Products, Inc. (NYSE American: UUU) will change its name to DeFi Capital Markets, Inc. effective October 19, 2026, and its stock is expected to trade under the ticker DCM on that date. The company also changed its fiscal year end from March 31 to December 31, and it said it anticipates discontinuing its legacy safety products business as it builds tokenization, proprietary trading and digital asset market-making operations.
Name change to DeFi Capital Markets, Inc. and ticker change to DCM take effect October 19, 2026; CUSIP is unchanged and no action is required from existing stockholders.
Fiscal year end moves from March 31 to December 31; the next fiscal year end is December 31, 2026, with a transition report on Form 10-K covering April 1, 2026 to December 31, 2026.
The company anticipates discontinuing its legacy business of designing and marketing safety products as its tokenization and digital asset initiatives gain traction.
The filing gives no financial results, revenue or profit figures.
Pulse Biosciences said its NANOPULSE-AF pivotal study of the nPulse Cardiac Catheter System for atrial fibrillation reached its enrollment target of 164 evaluable patients across 15 clinical sites. The company said enrollment finished three months ahead of its original 9-month timeline, and primary safety and effectiveness endpoints will be assessed at 6 and 12 months after ablation, so the filing contains no financial results or guidance.
Study reached its target of 164 evaluable patients across 15 clinical sites
First patients were treated in April 2026
Enrollment finished three months ahead of the original 9-month timeline
Primary endpoints will be assessed at 6 and 12 months post-ablation
60 Degrees Pharmaceuticals said it will stop enrolling its randomized hospital study of tafenoquine for severe babesiosis at 30 patients, three fewer than the 33 the data safety monitoring board (DSMB) recommended completing. The company cited limited statistical benefit from three more patients and the seasonal nature of the disease, which would delay unblinding to fall 2027. The DSMB's interim review identified no safety issues, but the filing states it did not establish whether the study met its endpoints.
As of October 1, 2026, 30 patients were enrolled against a planned 33
Primary and secondary endpoint results are expected in January 2027
The company will request a pre-sNDA meeting with the FDA in January 2027
Additional data from a separate expanded access study are expected in early November 2026
Barnwell Industries' board approved terminating its employee pension plan, effective on or about November 30, 2026, with benefits to be paid through annuity purchases. As of September 30, 2026, plan assets of about $12.8 million exceeded the estimated termination liability of $7.3 million and a related supplemental retirement obligation of about $1.8 million by about $3.7 million, before costs and taxes. The company expects any remaining surplus to revert to it in December 2026, but says the amount and timing are not assured, so shareholders may see a benefit only if the surplus is realized.
Board approved plan termination on September 30, 2026, effective on or about November 30, 2026.
As of September 30, 2026: plan assets about $12.8 million; estimated termination liability $7.3 million; supplemental retirement plan obligation about $1.8 million.
Estimated surplus of about $3.7 million before administrative and transaction costs, excise and other taxes, and any participant benefit increase.
Company anticipates reversion in December 2026; estimates are preliminary and may change materially.
Lucid Group reported that it produced 2,954 vehicles and delivered 3,806 in the quarter ended September 30, 2026. Deliveries exceeded production because the company reduced existing inventory as part of its previously announced operating reset. The filing does not include revenue, net income or cash flow, which Lucid says will be released with its third quarter 2026 earnings on November 9, 2026.
Q3 2026 production was 2,954 vehicles and deliveries were 3,806 vehicles.
Production declined sequentially, consistent with the elimination of a second shift at AMP-1 in June.
Lucid said demand for the Lucid Gravity continued to regain momentum.
The third quarter earnings call is set for November 9, 2026, with a shareholder Q&A platform opening October 23, 2026.
CECO Environmental notified Nasdaq that it will voluntarily withdraw the primary listing of its common stock and transfer it to the Texas Stock Exchange. The stock is expected to stop trading on Nasdaq at the close on October 16, 2026, and start trading on TXSE at the open on October 19, 2026, under the same ticker, CECO. The filing says the transfer is not expected to affect operations, financial condition, reporting obligations, or stockholders' rights, and that stockholders need not take any action.
Nasdaq trading as primary listing expected to end at market close on October 16, 2026
TXSE trading as primary listing expected to begin at market open on October 19, 2026
Ticker remains CECO and the company retains its existing CUSIP
Company says the transfer is not expected to affect operations, financial condition, or stockholder rights
Nano Dimension dismissed KPMG LLP as its independent auditor on September 28, 2026, and engaged Kesselman & Kesselman (PwC Israel) as successor, starting with the 2026 year-end audit and the Q3 2026 review. KPMG's report on internal control over financial reporting for fiscal 2025 contained an adverse opinion tied to a material weakness in accounting for acquisitions and discontinued operations, which shareholders should weigh alongside the change.
KPMG dismissed September 28, 2026; the Audit Committee approved the change.
KPMG's internal control report, dated March 31, 2026, was adverse, citing insufficient accounting resources affecting controls over acquisitions, including valuation of certain acquired intangible assets and discontinued operations.
PwC Israel engaged September 28, 2026, for the year ending December 31, 2026 audit and the quarter ending September 30, 2026 review.
KPMG's letter dated October 2, 2026, is filed as Exhibit 16.1.
Nasdaq-listed CEA Industries Inc. changed its name to BNB Standard Corporation, effective 12:01 a.m. Pacific Time on September 29, 2026, without stockholder approval. On October 2, 2026, the board also adopted amended and restated bylaws that lower the meeting quorum, change the voting standard, allow stockholder action by written consent, and add advancement of expenses and insurance requirements for directors and officers.
Name change effective September 29, 2026; common stock still trades as "BNC" on Nasdaq and warrants as "BNCWW" and "BNCWZ"; CUSIP numbers unchanged
Amended bylaws adopted October 2, 2026 reduce the stockholder meeting quorum to one-third of the voting power, from a majority
Amended bylaws allow stockholder action by written consent with consents from holders of at least a majority of voting power
Amended bylaws require expense advancement to directors and officers within 30 days of a written request
Tesla reported preliminary third-quarter 2026 production, delivery and energy storage deployment figures in a press release furnished as Exhibit 99.1 to a Form 8-K dated October 2, 2026. The release does not include net income or cash flow, which Tesla says will be announced with its Q3 2026 earnings on October 21, 2026, and the company notes these operating figures are not an indicator of quarterly financial results.
Vehicle deliveries totaled 486,532 in Q3 2026, including 478,237 Model 3/Y and 8,295 other models.
Vehicle production totaled 464,391 in Q3 2026, including 457,387 Model 3/Y and 7,004 other models.
Energy storage deployments totaled 13.7 GWh in the third quarter of 2026.
Tesla will report Q3 2026 financial results after market close on Wednesday, October 21, 2026, with a webcast at 5:30 p.m. Eastern Time.
Rivian reported that it produced 19,751 vehicles at its Normal, Illinois plant and delivered 19,248 vehicles in the quarter ending September 30, 2026. The company said these results were in line with its outlook and reaffirmed its 2026 delivery range of 65,000 to 70,000 vehicles. Full third quarter financial results are scheduled for release on October 29, 2026, which will give shareholders the revenue and profit figures not included in this update.
Q3 2026 production: 19,751 vehicles at the Normal, Illinois facility
Q3 2026 deliveries: 19,248 vehicles, which the company said were in line with its outlook
2026 delivery guidance of 65,000 to 70,000 vehicles reaffirmed
Third quarter 2026 financial results to be released October 29, 2026, after market close, with a webcast at 5:00 p.m. ET
Orchestra BioMed said that as of September 30, 2026, 330 patients had been randomized in the BACKBEAT pivotal trial of its AVIM Therapy, above the previously announced target of 316. The company reiterated that primary endpoint data are expected to be submitted for a late-breaking presentation at a major cardiovascular conference in the second quarter of 2027, with Medtronic planning marketing applications if results are positive. The filing contains no financial results, so the update is a clinical development milestone rather than a change in reported financial performance.
330 patients randomized as of September 30, 2026, versus a target of 316 to account for potential loss to follow-up
Trial protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis
Trial conducted at 81 sites across 13 countries with Medtronic plc as strategic collaborator
Primary endpoint results to be submitted for a late-breaking presentation in Q2 2027
Azitra said its safety review committee recommended that the Phase 1/2 trial of ATR04-484 for EGFR inhibitor-associated skin rash may proceed to Cohort 2, allowing enrollment and dosing to begin in that cohort. The filing contains no financial results, and the update concerns clinical progress only, based on a safety review of six patients from Cohort 1.
Safety review committee recommended proceeding to Cohort 2 after reviewing safety data from six patients in Cohort 1 (seven patients received a single 4g application).
Cohort 2 is expected to enroll approximately 24 patients receiving a 4g application once daily for 28 days.
The study is being conducted at six clinical sites, including MD Anderson Cancer Center and Yale University.
The FDA has granted Fast Track designation to ATR04-484 for EGFR inhibitor-associated rash, which affects approximately 150,000 patients annually in the United States.
Silexion Therapeutics said it has dosed the first patient worldwide in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, at Tel Aviv Sourasky Medical Center in Israel. The filing says additional sites in Israel and Germany are expected to join in the coming months, and the company refers to preliminary clinical readouts in the near term. The filing reports no financial results, guidance, or financing terms.
First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov); announced September 30, 2026
Trial plans an initial safety run-in cohort of approximately 18 patients, then a randomized cohort of approximately 166 patients
SIL204 is given with standard chemotherapy versus chemotherapy alone in patients with unresectable Stage 3 locally advanced pancreatic cancer with a confirmed KRAS mutation
Additional Israeli and German sites are expected to join in the coming months
Atlantic HPC Group, the target in Aperture AC's planned business combination, completed its acquisition of Valley Oasis Development LLC on September 23, 2026, adding two power contracts for 29 MW of aggregate contract demand and a one-acre land lease in Dyersburg, Tennessee. The filing says the acquisition raises Atlantic's total utility-approved capacity to 127 MW, of which 76 MW is under development, and the filing does not disclose the purchase price or the effect on financial results.
Acquisition of 100% of Valley Oasis membership interests completed September 23, 2026
Two power contracts with Dyersburg Electric System, each dated September 3, 2026, for 14.5 MW of contract demand
About 14.5 MW can be served on existing infrastructure after utility construction; the remaining 14.5 MW requires transformer upgrades
Land lease covers about one acre and expires in March 2036 without an option to extend
Avalanche Treasury Corporation completed a sale of 2,082,371.607744 AVAX tokens to Avalanche (BVI), Inc., a related foundation, on September 23, 2026, for aggregate gross proceeds of $15,000,000. The company said the tokens sold were its longest-dated locked AVAX holdings, which reduced its weighted average duration of locked AVAX to approximately 16.5 months, and that it expects to use the proceeds to reduce debt and for general corporate purposes.
Sold 2,082,371.607744 AVAX tokens to Avalanche (BVI), Inc. on September 23, 2026, in three tranches
Aggregate gross proceeds received were $15,000,000
Sold the longest-dated locked AVAX tokens, reducing weighted average duration of locked AVAX to about 16.5 months
Company expects to use proceeds to reduce debt and for general corporate purposes
Graf Global Corp. said its board elected on September 27, 2026 to extend the deadline to complete a business combination by one month, from September 27 to October 27, 2026. The company's governing documents allow up to three one-month extensions, which would push the deadline as far as December 27, 2026.
Original deadline: September 27, 2026; new deadline: October 27, 2026
Board can extend up to three times in one-month increments, to as late as December 27, 2026
Filing does not state a target company or deal terms
Greenland Energy Company sent a letter to shareholders on September 29, 2026, responding to a report from Fugazi Research that called the stock "uninvestable at any price above zero." The letter confirms the company is exploration-stage with no earnings, no production, no proved reserves and no drilled first well, and it disputes several points in the research report, including its cash burn and dilution claims.
Letter responds to Fugazi Research report; company states it has no earnings, no production, no proved reserves and has not drilled its first well.
Company says its 13-billion-barrel figure is the high-end 3U unrisked prospective resource estimate by Sproule ERCE; low case is about 1.1 billion barrels and best estimate about 4.2 billion barrels.
Letter states the company had $231,000 in the bank alongside a going-concern note, and that internal controls were reported as not yet effective.
Company paid £500,000 to preserve its right to earn up to a 70% working interest for two more years.
Silexion Therapeutics announced on September 28, 2026 preclinical findings that its lead candidate SIL204 uses naturally occurring serum lipoproteins to enter cancer cells and silence mutant KRAS. The study was in vitro, and the company said further pharmacokinetic and biodistribution studies are underway, so the results do not yet show clinical effect. The data supports the company's plan for systemic administration in its Phase 2/3 pancreatic cancer program.
In the study, depleting serum lipids cut SIL204 gene-knockdown efficiency by a statistically significant amount (P < 0.001).
Adding exogenous human LDL did not change gene-silencing potency compared with complete serum.
The company's Phase 2/3 trial targets locally advanced pancreatic cancer, with site initiation and regulatory clearances in Israel and Germany still in progress.
The filing contains no financial results, guidance or new capital figures.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.